Crystal form of pharmaceutically acceptable salt of sulfonylurea compound, preparation method therefor, pharmaceutical composition, and use thereof
By developing pharmaceutically acceptable new crystal forms of sulfonylurea compounds, the issues of insufficient activity and safety of existing compounds have been resolved, achieving more efficient NLRP3 inhibition and cytokine regulation, which is suitable for the treatment of a variety of diseases.
Patent Information
- Application Number
- PCT/CN2026/095644
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-16
- Filing Date
- 2026-05-08
- Publication Date
- 2026-11-19
AI Technical Summary
Existing sulfonylurea compounds, such as glibenclamide, have weak activity as NLRP3 inhibitors and may cause elevated serum liver enzyme levels in patients during clinical trials, leading to trial termination. There is a lack of effective pharmaceutically acceptable salt forms to improve their efficacy and safety in treating NLRP3-related diseases.
Novel crystal forms of pharmaceutically acceptable salts of sulfonylurea compounds, such as sodium, ammonium, or organic amine salts, specifically including crystal forms 2, 3, 4, and 5, are provided to enhance the solubility and stability of the compounds through specific preparation methods such as crystallization, filtration, and solvent treatment, thereby enhancing their efficacy as NLRP3 inflammasome inhibitors and cytokine modulators.
The new crystalline forms of sulfonylureas exhibit better cellular activity, pharmacokinetic half-life, and blood-brain barrier permeability, improving efficacy in animal models and making them suitable for treating a variety of diseases, including inflammatory diseases, autoimmune diseases, and central nervous system diseases.
Smart Images

Figure CN2026095644_19112026_PF_FP_ABST
Abstract
Description
Crystal forms of pharmaceutically acceptable salts of sulfonylureas, their preparation methods, pharmaceutical compositions, and uses.
[0001] This application claims priority to Chinese Patent Application No. 202510639314.4, filed on May 16, 2025, entitled "Pharmaceutically Acceptable Salts of Sulfonylureas and Their Preparation and Uses Thereof", the contents of which are to be understood as incorporated herein by reference. Technical Field
[0002] This application relates to, but is not limited to, the field of pharmaceutical technology, specifically to a pharmaceutically acceptable salt, crystal form, pharmaceutical composition of a sulfonylurea compound, and its preparation method and use. Background Technology
[0003] The nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome is a multimeric protein complex that activates cysteine asparate protease-1 (caspase-1), which in turn induces the maturation of interleukin (IL)-1β and IL-18. Under normal physiological conditions, activation of the NLRP3 inflammasome leads to the release of pro-inflammatory cytokines IL-1β and IL-18, both of which play crucial roles in pathogen response and defense. However, aberrant activation of the NLRP3 inflammasome can lead to neuroinflammation, which is closely associated with the development and progression of neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS). NLRP3 inhibitors, on the other hand, directly target NLRP3. Specifically, they interact directly with the NACHT or PYD domains of NLRP3. The possible effects include inhibiting the enzymatic activity of NLRP3 and inhibiting the interactions between NLRP3 cells, thereby affecting the assembly process (i.e., activation process) of the NLRP3 inflammasome.
[0004] Initially, glibenclamide, a sulfonylurea compound, was found to be an effective NLRP3 inhibitor when screening a library of diarylsulfonylureas for interleukin-1β (IL-1β) secreted by human monocytes (J. Pharmacol. Experimental Therapeutics 2001, 299(1), 187-197.), but its activity was weak. Subsequently, these compounds were further optimized and their mechanisms were preliminarily investigated, hypothesizing that they act by inhibiting GST omega 1-1. Further work revealed that these compounds act by inhibiting NLRP3 (J. Biol. Chem. 2003, 278, 16567-16578.). One of the glibenclamide derivatives, CRID3 or CP456,773, was renamed MCC950 and was found to be an effective inhibitor of the NLRP3 inflammasome (Nat. Med. 2015, 21(3), 248-255.). MCC950 was clinically tested in rheumatoid arthritis, but the trial was likely terminated due to elevated serum liver enzyme levels in patients. MCC950 exerts its effect by binding to the Walker B motif in the NACHT domain of NLRP3 and blocking NLRP3-mediated ATP hydrolysis. Subsequently, MCC950 has been used as a tool compound in a wide range of in vitro and in vivo studies involving NLRP3-related diseases. This tool compound, used in conjunction with a range of target validation techniques, has demonstrated significant activity against NLRP3 in numerous diseases, including cryopyrin-associated periodic syndrome (CAPS), inflammatory bowel disease (IBD), non-alcoholic fatty liver disease (NASH), gout, multiple sclerosis, stroke, Alzheimer's disease, and Parkinson's disease. Summary of the Invention
[0005] The following is an overview of the subject matter described in detail in this application. This overview is not intended to limit the scope of protection of this application.
[0006] The first aspect of this application provides a crystal form of a pharmaceutically acceptable salt of a compound of Formula I, wherein the pharmaceutically acceptable salt of the compound of Formula I is a sodium salt; optionally, the crystal form is crystal form 2, crystal form 3, crystal form 4 or crystal form 5; the structural formula of the compound of Formula I is:
[0007] A second aspect of this application provides a pharmaceutical composition comprising one or more crystal forms of pharmaceutically acceptable salts of compounds of Formula I above, and optionally, pharmaceutically acceptable excipients.
[0008] A third aspect of this application provides a crystal form of a pharmaceutically acceptable salt of the compound of formula I above, or the pharmaceutical composition described above, for use as:
[0009] (i) NLRP3 inflammasome inhibitors; and / or
[0010] (ii) One or more regulators of IL-1β, IL-17, IL-18, IL-1α, IL-37, IL-33 and Th17 cells.
[0011] The fourth aspect of this application provides a crystalline form of a pharmaceutically acceptable salt of the compound of formula I above, or the pharmaceutical composition thereof, for use in the treatment or prevention of a disease, symptom, or condition, wherein the disease, symptom, or condition is selected from the group consisting of:
[0012] (i) Immune system diseases, symptoms, or conditions;
[0013] (ii) Inflammatory diseases, symptoms or conditions or autoimmune diseases, symptoms or conditions;
[0014] (iii) Skin diseases, conditions or illnesses;
[0015] (iv) Cardiovascular diseases, conditions, or illnesses;
[0016] (v) tumor;
[0017] (vi) Diseases, symptoms or conditions of the kidney system;
[0018] (vii) Gastrointestinal diseases, symptoms or conditions;
[0019] (viii) Respiratory diseases, symptoms, or conditions;
[0020] (ix) Endocrine system disorders, symptoms, or conditions;
[0021] (x) Diseases, symptoms, or conditions of the central nervous system (CNS); and / or
[0022] (xi) Local or systemic infection.
[0023] The fifth aspect of this application provides the use of a pharmaceutically acceptable crystal form of a salt of a compound of formula I or a composition thereof in the preparation of a medicament for treating or preventing a disease, symptom, or condition, wherein the disease, symptom, or condition is selected from the group consisting of:
[0024] (i) Immune system diseases, symptoms, or conditions;
[0025] (ii) Inflammatory diseases, symptoms or conditions or autoimmune diseases, symptoms or conditions;
[0026] (iii) Skin diseases, conditions or illnesses;
[0027] (iv) Cardiovascular diseases, conditions, or illnesses;
[0028] (v) tumor;
[0029] (vi) Diseases, symptoms or conditions of the kidney system;
[0030] (vii) Gastrointestinal diseases, symptoms or conditions;
[0031] (viii) Respiratory diseases, symptoms, or conditions;
[0032] (ix) Endocrine system disorders, symptoms, or conditions;
[0033] (x) Diseases, symptoms, or conditions of the central nervous system (CNS); and / or
[0034] (xi) Local or systemic infection.
[0035] The sixth aspect of this application provides a method for treating or preventing a disease, symptom, or condition, comprising administering to a subject with a corresponding need a pharmaceutically acceptable crystal form of a compound of Formula I or a pharmaceutical composition thereof, wherein the disease, symptom, or condition is selected from the group consisting of:
[0036] (i) Immune system diseases, symptoms, or conditions;
[0037] (ii) Inflammatory diseases, symptoms or conditions or autoimmune diseases, symptoms or conditions;
[0038] (iii) Skin diseases, conditions or illnesses;
[0039] (iv) Cardiovascular diseases, conditions, or illnesses;
[0040] (v) tumor;
[0041] (vi) Diseases, symptoms or conditions of the kidney system;
[0042] (vii) Gastrointestinal diseases, symptoms or conditions;
[0043] (viii) Respiratory diseases, symptoms, or conditions;
[0044] (ix) Endocrine system disorders, symptoms, or conditions;
[0045] (x) Diseases, symptoms, or conditions of the central nervous system (CNS); and / or
[0046] (xi) Local or systemic infection.
[0047] After reading and understanding the accompanying diagrams and detailed descriptions, the other aspects can be understood.
[0048] Overview of the attached figures
[0049] The accompanying drawings are used to provide an understanding of the technical solutions of this application and constitute a part of the specification. They are used together with the embodiments of this application to explain the technical solutions of this application and do not constitute a limitation on the technical solutions of this application.
[0050] Figure 1(a) shows the results of serum IL-1β detection at 2.5 h and 4 h after LPS-induced sepsis model establishment;
[0051] Figure 1(b) shows the statistical results of mouse survival rate after LPS-induced sepsis model establishment;
[0052] Figure 2 shows the IL-1β level in the ascites fluid of mice in an MSU-induced mouse peritonitis model;
[0053] Figures 3 and 4 show the plasma pharmacokinetic analysis results of C57 mice after administration of the compound and control drug MCC950 in Example 1 of this application;
[0054] Figures 5 and 6 show the plasma pharmacokinetic analysis results of SD rats after administration of the compound and control drug MCC950 in Example 1 of this application;
[0055] Figure 7 shows the X-ray powder diffraction pattern of crystal form 2 using Cu-Ka radiation;
[0056] Figure 8 shows the DSC curve of crystal form 2;
[0057] Figure 9 shows the TGA curve of crystal form 2;
[0058] Figure 10 shows the X-ray powder diffraction pattern of crystal form 3 using Cu-Ka radiation;
[0059] Figure 11 shows the DSC curve of crystal form 3;
[0060] Figure 12 shows the TGA curve of crystal form 3;
[0061] Figure 13 shows the X-ray powder diffraction pattern of crystal form 4 using Cu-Ka radiation;
[0062] Figure 14 shows the DSC curve of crystal form 4;
[0063] Figure 15 shows the TGA curve of crystal form 4;
[0064] Figure 16 shows the X-ray powder diffraction pattern of crystal form 5 using Cu-Ka radiation;
[0065] Figure 17 shows the DSC curve of crystal form 5;
[0066] Figure 18 shows the TGA curve of crystal form 5;
[0067] Figure 19 shows the plasma pharmacokinetic analysis results of compound (crystal form 2) in Example 5;
[0068] Figure 20 shows the plasma pharmacokinetic analysis results of the control drug AZD4144 in parallel tests;
[0069] Figure 21 shows the effect of compound 5 (crystal form 2) on cartilage damage in a collagen-induced rheumatoid arthritis (CIA) model;
[0070] Figure 22 shows the inhibitory effect of compound 5 (crystal form 2) on bone injury development in a sodium iodoacetate (MIA)-induced osteoarthritis (OA) model.
[0071] Detailed Explanation
[0072] Since the solubility and stability of active ingredients are crucial factors for pharmaceuticals, exploring new salt forms of pharmaceutically usable compounds can further improve the overall performance of pharmaceutical products and expand the range of available materials. Because the salt forms of specific compounds have unique structures, they possess different physical properties, such as morphology, melting point, solubility, hygroscopicity, and stability, thus exhibiting different behaviors in drug formulation, therapeutic activity, and chemical and physical stability.
[0073] This application provides a pharmaceutically acceptable salt of a compound represented by Formula I, wherein the pharmaceutically acceptable salt of the compound represented by Formula I is a metal salt, an ammonium salt, or an organic amine salt.
[0074] In one exemplary embodiment, the structural formula of the compound of formula I is:
[0075] In one exemplary embodiment, the metal salt is selected from any one of sodium salt, potassium salt, lithium salt, and calcium salt.
[0076] In one exemplary embodiment, the organic amine salt may be a tris(hydroxymethyl)aminomethane (Tris) salt.
[0077] In one exemplary embodiment, the pharmaceutically acceptable salt of the compound of formula I has the structural formula of any of the following:
[0078] In one exemplary embodiment, the pharmaceutically acceptable salt of the compound of formula I is a sodium salt or a potassium salt.
[0079] In one exemplary embodiment, the sodium salt is a crystalline sodium salt, including sodium salt hydrates.
[0080] In one exemplary embodiment, the sodium salt hydrate may be any one of hemihydrate, monohydrate, dihydrate, trihydrate, pentahydrate, hexahydrate, heptahydrate, and decahydrate.
[0081] This application also provides a crystal form of a pharmaceutically acceptable salt of a compound of formula I, wherein the pharmaceutically acceptable salt of the compound of formula I is a sodium salt; the structural formula of the compound of formula I is:
[0082] In one exemplary embodiment, the crystal form is crystal form 2, crystal form 3, crystal form 4 or crystal form 5.
[0083] In one exemplary embodiment, the crystal form is a sodium salt trihydrate.
[0084] In one exemplary embodiment, the X-ray powder diffraction pattern of the crystal form 2 using Cu-Ka radiation has characteristic peaks at the following positions with a value of 2Theta: 5.42±0.2°, 10.57±0.2°, and 19.41±0.2°.
[0085] In one exemplary embodiment, the X-ray powder diffraction pattern of the crystal form 2 using Cu-Ka radiation also has characteristic peaks at one or more of the following positions where 2Theta is: 10.8±0.2°, 11.87±0.2°, 14.11±0.2°, 15.21±0.2°, 16.22±0.2°, 17.11±0.2°, 21.15±0.2°, 21.57±0.2°, 22.35±0.2°, 23.55±0.2°, 24.16±0.2°.
[0086] In one exemplary embodiment, the crystal form 2 has an XRPD pattern as shown in FIG7.
[0087] In one exemplary embodiment, the differential thermal analysis spectrum of the crystal form 2 has an endothermic peak at a peak temperature of 87.76°C and an exothermic peak at a peak temperature of 140.75°C.
[0088] In one exemplary embodiment, the differential thermal analysis (DSC) spectrum of the crystal form 2 is shown in Figure 8.
[0089] In one exemplary embodiment, the thermogravimetric analysis (TGA) spectrum of the crystal form 2 shows a weight loss of 0.875% at 27-50°C and a weight loss of 10.938% at 50-120°C.
[0090] In one exemplary embodiment, the thermogravimetric analysis spectrum of the crystal form 2 is shown in Figure 9.
[0091] In one exemplary embodiment, the X-ray powder diffraction pattern of the crystal form 3 using Cu-Ka radiation has characteristic peaks at the following positions with a value of 2Theta: 4.60±0.2°, 5.72±0.2°, 5.98±0.2°, 7.23±0.2°, 14.50±0.2°, 15.40±0.2°, and 18.39±0.2°.
[0092] In one exemplary embodiment, the X-ray powder diffraction pattern of the crystal form 3 using Cu-Ka radiation also has characteristic peaks at one or more of the following positions for 2Theta: 8.35±0.2°, 8.74±0.2°, 11.97±0.2°, 14.95±0.2°, 15.94±0.2°, 17.18±0.2°, 20.62±0.2°, 22.58±0.2°, and 26.99±0.2°.
[0093] In one exemplary embodiment, the crystal form 3 has an XRPD pattern as shown in FIG10.
[0094] In one exemplary embodiment, the differential thermal analysis spectrum of the crystal form 3 has an endothermic peak at a peak temperature of 142.48°C and an exothermic peak at a peak temperature of 217.12°C.
[0095] In one exemplary embodiment, the differential thermal analysis (DSC) spectrum of the crystal form 3 is shown in Figure 11.
[0096] In one exemplary embodiment, the thermogravimetric analysis (TGA) spectrum of the crystal form 3 shows a weight loss of 2.9% at 30-155°C.
[0097] In one exemplary embodiment, the thermogravimetric analysis spectrum of the crystal form 3 is shown in Figure 12.
[0098] In one exemplary embodiment, the X-ray powder diffraction pattern of the crystal form 4 using Cu-Ka radiation has characteristic peaks at the following positions with a 2Theta value: 5.08±0.2° and 6.88±0.2°.
[0099] In one exemplary embodiment, the X-ray powder diffraction pattern of the crystal form 4 using Cu-Ka radiation also has characteristic peaks at one or more of the following positions for 2Theta: 4.75±0.2°, 5.85±0.2°, 9.91±0.2°, 14.17±0.2°, 18.84±0.2°, and 20.58±0.2°.
[0100] In one exemplary embodiment, the crystal form 4 has an XRPD pattern as shown in FIG13.
[0101] In one exemplary embodiment, the differential thermal analysis spectrum of the crystal form 4 has endothermic peaks at peak temperatures of 63.89°C and 121.85°C, and an exothermic peak at peak temperature of 143.63°C.
[0102] In one exemplary embodiment, the differential thermal analysis (DSC) spectrum of the crystal form 4 is shown in Figure 14.
[0103] In one exemplary embodiment, the thermogravimetric analysis (TGA) spectrum of crystal form 4 shows a weight loss of 2.19% at 30-94°C and a weight loss of 4.426% at 94-131°C.
[0104] In one exemplary embodiment, the thermogravimetric analysis spectrum of crystal form 4 is shown in Figure 15.
[0105] In one exemplary embodiment, the X-ray powder diffraction pattern of the crystal form 5 using Cu-Ka radiation has characteristic peaks at the following positions with a value of 2Theta: 5.26±0.2°, 8.09±0.2°, 15.31±0.2°, and 20.18±0.2°.
[0106] In one exemplary embodiment, the X-ray powder diffraction pattern of the crystal form 5 using Cu-Ka radiation also has characteristic peaks at one or more of the following positions where 2Theta is: 9.29±0.2°, 10.49±0.2°, 12.99±0.2°, 15.72±0.2°, 23.17±0.2°, 23.61±0.2°, 24.30±0.2°.
[0107] In one exemplary embodiment, the crystal form 5 has an XRPD pattern as shown in FIG16.
[0108] In one exemplary embodiment, the differential thermal analysis spectrum of the crystal form 5 has endothermic peaks at peak temperatures of 64.08°C and 226.37°C.
[0109] In one exemplary embodiment, the differential thermal analysis (DSC) spectrum of the crystal form 5 is shown in Figure 17.
[0110] In one exemplary embodiment, the thermogravimetric analysis (TGA) spectrum of the crystal form 5 shows a weight loss of 0.419% at 30-50°C and a weight loss of 1.802% at 50-100°C.
[0111] In one exemplary embodiment, the thermogravimetric analysis spectrum of the crystal form 5 is shown in Figure 18.
[0112] This application also provides a method for preparing a pharmaceutically acceptable salt of the compound represented by Formula I above, comprising the following steps:
[0113] Step 1): 3-Halo-2-nitrobenzaldehyde reacts with dimethylamine via a reductive amination reaction to generate compound a;
[0114] Step 2): Compound a reacts with thiol HSR 1 The reaction produces compound b;
[0115] Step 3): Compound b is oxidized in the presence of a chlorinating reagent to synthesize sulfonyl chloride, which then reacts with an inorganic ammonia reagent to generate compound c;
[0116] Step 4): Compound c reacts with compound d and a carbonylating agent to generate compound e.
[0117] Step 5): Compound e undergoes a reduction reaction to produce compound I.
[0118] Step 6): Compound I reacts with a base to form a salt.
[0119] In an exemplary embodiment, in step 6), the base is an inorganic base or an organic base;
[0120] Optionally, the base is NaOH, KOH, LiOH, Ca(OH)2, NH4OH or tris(hydroxymethyl)aminomethane (Tris).
[0121] In one exemplary embodiment, in step 1), X is selected from any one of fluorine, chlorine, bromine or iodine; preferably, X is Br.
[0122] In one exemplary embodiment, in step 1), the reducing agent is NaBH(OAc)3.
[0123] In one exemplary embodiment, in step 1), the solvent for the reaction is dichloromethane (DCM).
[0124] In one exemplary embodiment, in step 1), the reaction temperature is room temperature and the reaction time is 1-24 hours.
[0125] In one exemplary embodiment, in step 2), HSR 1 and R in compound b 1 Selected from arylalkyl, alkenylalkyl, arylynyl or alkyl; preferably, R 1 It is an arylalkyl group; more preferably, R 1 It is benzyl.
[0126] In one exemplary embodiment, in step 2), the reaction undergoes a coupling reaction in the presence of a catalyst, a ligand, and a basic reagent;
[0127] Optionally, the catalyst is Pd2(dba)3;
[0128] Optionally, the ligand is Xantphos;
[0129] Optionally, the alkaline reagent is N,N-diisopropylethylamine (DIEA).
[0130] In one exemplary embodiment, in step 2), the solvent for the reaction is toluene.
[0131] In one exemplary embodiment, in step 2), the reaction temperature is 115°C and the reaction time is 12 hours.
[0132] In one exemplary embodiment, in step 3), the chlorinating agent is N-chlorosuccinimide (NCS).
[0133] In an exemplary embodiment, in step 4), the carbonylating agent is selected from one or more of phosgene, triphosgene, dimethyl carbonate, and N,N'-carbonyldiimidazole (CDI); preferably, the carbonylating agent is triphosgene.
[0134] In one exemplary embodiment, in step 4), the reaction takes place in an alkaline environment;
[0135] Optionally, the basic reagent is N,N-diisopropylethylamine (DIEA);
[0136] Optionally, the solvent for the reaction is dichloromethane.
[0137] In one exemplary embodiment, in step 4), the reaction temperature is 50°C and the reaction time is 2 hours.
[0138] This application also provides a method for preparing a pharmaceutically acceptable crystal form of the compound of formula I, wherein the crystal form is crystal form 2; the preparation method includes:
[0139] Method A: The compound of formula I is mixed with an alkali in an aqueous solution, crystallized, filtered, and dried at room temperature to obtain crystal form 2; or
[0140] Method B: The low crystallinity sodium salt of the compound of formula I was placed in a stability chamber at 25°C and 92.5% RH for 24 hours to obtain crystal form 2.
[0141] In one exemplary embodiment, the method for preparing the low-crystallinity sodium salt of the compound of formula I is as follows: after mixing the compound of formula I with an alkali in an aqueous solution, crystallizing, filtering, purifying, and freeze-drying are performed to obtain the low-crystallinity sodium salt of the compound of formula I.
[0142] In one exemplary embodiment, the base is NaOH.
[0143] This application also provides a method for preparing a pharmaceutically acceptable crystal form of a compound of formula I, wherein the crystal form is crystal form 3, crystal form 4, or crystal form 5; the preparation method includes:
[0144] The low-crystallinity sodium salt of the compound of formula I is mixed with an organic solvent and pulped at room temperature for 24 hours to obtain the product.
[0145] In one exemplary embodiment, the organic solvent used in the crystal form 3 is acetone / n-heptane;
[0146] Optionally, in the organic solvent, the volume ratio (v / v) of acetone to n-heptane is 1:9.
[0147] In one exemplary embodiment, the organic solvent used in crystal form 4 is isopropanol.
[0148] In one exemplary embodiment, the organic solvent used in the crystal form 5 is acetone.
[0149] This application also provides a pharmaceutically acceptable salt of the compound of formula I prepared by the above method and its crystal form.
[0150] This application also provides a pharmaceutical composition comprising one or more of a pharmaceutically acceptable salt of a compound of formula I and a crystal form of the pharmaceutically acceptable salt of the compound of formula I.
[0151] In one exemplary embodiment, the pharmaceutical composition further includes pharmaceutically acceptable excipients.
[0152] This application also provides a pharmaceutically acceptable salt of a compound of formula I, a crystal form of the pharmaceutically acceptable salt of the above-mentioned compound of formula I, or the pharmaceutical composition thereof, for use as:
[0153] (i) NLRP3 inflammasome inhibitors; and / or
[0154] (ii) One or more regulators of IL-1β, IL-17, IL-18, IL-1α, IL-37, IL-33 and Th17 cells.
[0155] This application also provides a pharmaceutically acceptable salt of a compound of formula I, a crystal form of the pharmaceutically acceptable salt of the above-mentioned compound of formula I, or a pharmaceutical composition thereof, for use in the treatment or prevention of a disease, symptom, or condition, wherein the disease, symptom, or condition is selected from the group consisting of:
[0156] (i) Immune system diseases, symptoms, or conditions;
[0157] (ii) Inflammatory diseases, symptoms or conditions or autoimmune diseases, symptoms or conditions;
[0158] (iii) Skin diseases, conditions or illnesses;
[0159] (iv) Cardiovascular diseases, conditions, or illnesses;
[0160] (v) tumor;
[0161] (vi) Diseases, symptoms or conditions of the kidney system;
[0162] (vii) Gastrointestinal diseases, symptoms or conditions;
[0163] (viii) Respiratory diseases, symptoms, or conditions;
[0164] (ix) Endocrine system disorders, symptoms, or conditions;
[0165] (x) Diseases, symptoms, or conditions of the central nervous system (CNS); and / or
[0166] (xi) Local or systemic infection.
[0167] This application also provides the use of a pharmaceutically acceptable salt of a compound of formula I, a crystal form of the pharmaceutically acceptable salt of the above-mentioned compound of formula I, or the use of said pharmaceutical composition in the preparation of a medicament for treating or preventing a disease, symptom, or condition, wherein said disease, symptom, or condition is selected from the group consisting of:
[0168] (i) Immune system diseases, symptoms, or conditions;
[0169] (ii) Inflammatory diseases, symptoms or conditions or autoimmune diseases, symptoms or conditions;
[0170] (iii) Skin diseases, conditions or illnesses;
[0171] (iv) Cardiovascular diseases, conditions, or illnesses;
[0172] (v) tumor;
[0173] (vi) Diseases, symptoms or conditions of the kidney system;
[0174] (vii) Gastrointestinal diseases, symptoms or conditions;
[0175] (viii) Respiratory diseases, symptoms, or conditions;
[0176] (ix) Endocrine system disorders, symptoms, or conditions;
[0177] (x) Diseases, symptoms, or conditions of the central nervous system (CNS); and / or
[0178] (xi) Local or systemic infection.
[0179] This application also provides a method for treating or preventing a disease, symptom, or condition, comprising administering to a subject with a corresponding need a pharmaceutically acceptable salt of a compound of formula I, a crystal form of a pharmaceutically acceptable salt of a compound of formula I, or the pharmaceutical composition thereof, wherein the disease, symptom, or condition is selected from the group consisting of:
[0180] (i) Immune system diseases, symptoms, or conditions;
[0181] (ii) Inflammatory diseases, symptoms or conditions or autoimmune diseases, symptoms or conditions;
[0182] (iii) Skin diseases, conditions or illnesses;
[0183] (iv) Cardiovascular diseases, conditions, or illnesses;
[0184] (v) tumor;
[0185] (vi) Diseases, symptoms or conditions of the kidney system;
[0186] (vii) Gastrointestinal diseases, symptoms or conditions;
[0187] (viii) Respiratory diseases, symptoms, or conditions;
[0188] (ix) Endocrine system disorders, symptoms, or conditions;
[0189] (x) Diseases, symptoms, or conditions of the central nervous system (CNS); and / or
[0190] (xi) Local or systemic infection.
[0191] In one exemplary embodiment, the disease, symptom, or condition is selected from the group consisting of:
[0192] Constitutive inflammation includes cryptothermal protein-associated cycle syndrome (CAPS), Mukel-Wells syndrome (MWS), familial cold autoinflammatory syndrome (FCAS), neonatal multisystem inflammatory disease (NOMID), familial Mediterranean fever (FMF), TNF receptor-associated cycle syndrome (TRAPS), mevalonate kinase deficiency (MKD), hyperimmunoglobulinemia D and periodic fever syndrome (HIDS), interleukin-1 receptor antagonist deficiency (DIRA), Majid syndrome, pyogenic arthritis, pyoderma gangrenosa and acne syndrome (PAPA), A20 haploinadequacy (HA20), childhood granulomatous arthritis (PGA), PLAC2-associated antibody deficiency and immune dysregulation (PLAID), PLAC2-associated autoinflammation, antibody deficiency and immune dysregulation (APLAID), sideroblastic anemia with B-cell immunodeficiency, periodic fever and developmental retardation (SIFD);
[0193] Autoimmune diseases, including multiple sclerosis (MS), type 1 diabetes, psoriasis, rheumatoid arthritis, Behcet's disease, Sjögren's syndrome, and Schnitz's syndrome;
[0194] Macrophage activation syndrome;
[0195] Blau syndrome;
[0196] Respiratory diseases, including chronic obstructive pulmonary disease (COPD), asthma such as allergic asthma and steroid-resistant asthma, asbestosis, silicosis, and cystic fibrosis;
[0197] Dermatitis, including contact dermatitis;
[0198] Central nervous system diseases, including Parkinson's disease, Alzheimer's disease, motor neuron disease, Huntington's disease, cerebral malaria, and brain damage caused by pneumococcal meningitis;
[0199] Metabolic diseases, including type 2 diabetes, atherosclerosis, obesity, gout, and pseudogout;
[0200] Eye diseases, including those of the ocular epithelium, age-related macular degeneration (AMD), uveitis, corneal infections, and dry eye syndrome;
[0201] Kidney diseases, including chronic kidney disease, oxalate nephropathy, nephrocalcinosis, and diabetic nephropathy;
[0202] Liver diseases, including nonalcoholic steatohepatitis (NASH) and alcoholic liver disease;
[0203] Inflammatory skin reactions, including contact hypersensitivity and sunburn;
[0204] Joint inflammatory responses, including osteoarthritis, systemic juvenile idiopathic arthritis, adult-onset Stiebel disease, and relapsing polychondritis;
[0205] Viral infections, including alpha viruses (Chekungunya virus, Ross River virus) and flaviviruses (dengue virus, Zika virus), influenza virus, and HIV;
[0206] Hidradenitis suppurativa (HS) and other skin conditions that cause cysts;
[0207] Cancer, including metastatic lung cancer, pancreatic cancer, stomach cancer, myelodysplastic syndrome, and leukemia;
[0208] Polymyositis;
[0209] Stroke, including ischemic stroke;
[0210] Myocardial infarction, including recurrent myocardial infarction;
[0211] Congestive heart failure;
[0212] embolism;
[0213] Cardiovascular diseases;
[0214] Graft-host disease;
[0215] hypertension;
[0216] colitis;
[0217] worm infection;
[0218] Bacterial infection;
[0219] septicemia;
[0220] Septic shock;
[0221] Abdominal aortic aneurysm;
[0222] Wound healing;
[0223] Depression, psychological stress;
[0224] Local ischemia-reperfusion injury and any disease in which an individual has been identified as carrying a germline or somatic non-silent mutation in NLRP3.
[0225] In one exemplary embodiment, the disease, symptom, or condition is selected from the group consisting of:
[0226] (i) Autoinflammatory diseases, such as cryptothermal protein-associated cycle syndrome (CAPS), Mukel-Wells syndrome (MWS), familial cold autoinflammatory syndrome (FCAS), familial Mediterranean fever (FMF), neonatal onset of multisystem inflammatory disease (NOMID), tumor necrosis factor (TNF) receptor-associated cycle syndrome (TRAPS), hyperimmunoglobulinemia D and periodic fever syndrome (HIDS), interleukin-1 receptor antagonist deficiency (DIRA), Majid syndrome or pyogenic arthritis, pyoderma gangrene and acne syndrome (PAPA);
[0227] (ii) Parkinson's disease or Huntington's disease;
[0228] (iii) Gout or juvenile idiopathic arthritis;
[0229] (iv) Nonalcoholic steatohepatitis (NASH);
[0230] (v) Oxalate nephropathy or nephrocalcinosis;
[0231] (vi) uveitis;
[0232] (vii) Hidradenitis suppurativa (HS);
[0233] (viii) Myelodysplastic syndrome, macrophage activation syndrome, Schnitz syndrome, adult-onset Stiebel syndrome, or Behcet's disease; or
[0234] (ix) Sepsis, septic shock.
[0235] The compounds of this application, or their salts or crystal forms thereof, exhibit better cellular activity, superior pharmacokinetic half-life and exposure, better blood-brain barrier permeability, and better efficacy in animal models.
[0236] Other features and advantages of this application will be set forth in the following description, or may be learned by practicing this application. Other advantages of this application can be realized and obtained through the solutions described in the specification and accompanying drawings. Detailed Implementation
[0237] To better understand this application, specific embodiments are described below. However, the scope of this application is not limited to these embodiments, nor are they intended to limit the scope of the application. Without departing from the spirit and scope of this application, those skilled in the art can make any modifications or changes to the technical solutions of this application, and such modifications and changes are also included within the scope of this application.
[0238] the term
[0239] In this document, the term "pharmaceutically acceptable" refers to compounds, materials, compositions, and / or dosage forms that, within the bounds of reliable medical judgment, are suitable for use in contact with human and animal tissues without excessive toxicity, irritation, allergic reactions, or other problems or complications, in proportion to a reasonable benefit / risk ratio.
[0240] In this document, the term "pharmaceutically acceptable salt" refers to the base addition salt of the compound of Formula I of this application. Here, the base may be an inorganic base or an organic base. The inorganic base may be, for example, hydroxides of sodium, potassium, lithium, calcium, magnesium, manganese, iron, zinc, or aluminum. The organic base includes basic amino acids (e.g., arginine, lysine, histidine), ammonia, primary amines, secondary amines, tertiary amines, cyclic amines (such as piperidine, morpholine, piperazine), tris(hydroxymethyl)aminomethane, etc.
[0241] In this document, the term "pharmaceuticalally acceptable excipient" refers to those excipients that do not cause significant irritation to the organism and do not impair the bioactivity and properties of the active compound. Suitable excipients are well known to those skilled in the art, such as carbohydrates, waxes, water-soluble and / or water-swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, water, etc.
[0242] In this article, the words “comprise” or “comprise” and their English variants such as comprises or comprising should be understood as having an open, non-exclusive meaning, that is, “including but not limited to”.
[0243] In this document, the term "pharmaceutical composition" refers to one or more compounds of this application or pharmaceutically acceptable salts thereof, or crystal forms of said salts, and a mixture thereof with pharmaceutically acceptable excipients. The purpose of a pharmaceutical composition is to facilitate the administration of a pharmaceutically acceptable salt of a compound of this application, or a crystal form of said salt, to an organism.
[0244] In this document, the term "treatment" means administering the compound described in this application or a pharmaceutically acceptable salt thereof, or a crystalline form or formulation of said salt, to improve or eliminate a disease or one or more symptoms associated with said disease, and includes:
[0245] (i) Suppress the disease or disease state, that is, curb its development;
[0246] (ii) Relieve the disease or disease state, even if the disease or disease state subsides.
[0247] In this document, the term "prevention" means administering the compound described in this application or a pharmaceutically acceptable salt thereof, or a crystalline form or formulation of said salt, to prevent a disease or one or more symptoms associated with said disease, and includes:
[0248] Preventing the occurrence of disease or disease state in subjects (e.g., mammals), especially when such subjects are susceptible to the disease state but have not yet been diagnosed with it.
[0249] The compounds of this application, pharmaceutically acceptable salts of the compounds, or crystal forms of the salts can be prepared by a variety of synthetic methods, including the specific embodiments listed below, embodiments formed by combining them with other chemical synthetic methods, and equivalent substitutions well known to those skilled in the art. Preferred embodiments include, but are not limited to, the embodiments of this application.
[0250] The chemical reactions in the specific embodiments of this application are carried out in a suitable solvent, which must be suitable for the chemical changes of this application and the reagents and materials required therefor. In order to obtain the compounds of this application, pharmaceutically acceptable salts of said compounds, or crystal forms of said salts, it is sometimes necessary for those skilled in the art to modify or select the synthesis steps or reaction processes based on existing embodiments.
[0251] Unless otherwise specified, all raw materials / components used in this application are commercially available products well known to those skilled in the art.
[0252] This application uses the following abbreviations: THF: Tetrahydrofuran; 2M in THF: 2 mol / L tetrahydrofuran solution; DCM: Dichloromethane; NaBH(OAc)3: Sodium triacetoxyborohydride; HOAc: Acetic acid; HSBn: Benzyl mercaptan; Pd2(dba)3: Tris(dibenzylacetone)palladium; XantPhos: 4,5-bis(diphenylphosphine-9,9-dimethyloxanthracene; DIEA: N,N-diisopropylethylamine; Toluene: Toluene; NCS: N-chlorosuccinimide; Triphosgene: Triphosgene; ACN: Acetonitrile; AZD4144: (2S)-3-({4-[2-hydroxy-4-(trifluoromethyl)phenyl]benzo[2,1-d][1,2]diazacyclohexam-1-yl}amino)prop-1,2-diol, CAS No. 2890191-41-8; Counts; 2Theta; Weight; Weight Percent Loss; Equilibrate; Ramp 10.00℃ / min to 300.00℃; or Temperature; Peak temperature; Onset X; Heat Flow (normalized); Enthalpy (normalized); LCMS; HPLC.
[0253] Unless otherwise specified, all chemical reagents were purchased from Shanghai Jizhi Biochemical Technology Co., Ltd.
[0254] The instrument model information involved in the experiment is as follows:
[0255] LCMS: Agilent 1260-G6125 LC-MS / MS, reaction monitoring and compound identification use the default ESI mode; pharmacokinetic (DMPK) testing uses SIM mode.
[0256] HPLC detection: Agilent 1260 high performance liquid chromatograph.
[0257] Preparative HPLC: Xiaohe LC5100 preparative high performance liquid chromatograph.
[0258] NMR instrument: CAS Oxford Quantum-1plus AS400 NMR.
[0259] Unless otherwise specified, preparative HPLC uses a gradient elution from 10% acetonitrile / water to 100% acetonitrile / water with 0.05% (v / v) trifluoroacetic acid added to the mobile phase; LCMS uses a gradient elution from 10% acetonitrile / water to 100% acetonitrile with 0.1% (v / v) formic acid added to the mobile phase.
[0260] Unless otherwise specified, the ratios of solvents or liquid reagents mentioned in this article are volume ratios.
[0261] Liquid chromatography detection methods
[0262] Unless otherwise specified, all liquid chromatography detections in this application were performed using an Agilent 1260 series high-performance liquid chromatograph. The HPLC detection methods are shown in the table below.
[0263] HPLC detection parameters:
[0264] XRPD detection method:
[0265] Spread an appropriate amount of sample evenly on a zero-background silicon wafer, gently press to flatten the surface, and acquire XRPD patterns using an X-ray powder diffractometer. The detection parameters are shown in the table below.
[0266] XRPD detection parameters
[0267] TGA detection method
[0268] Place 2-5 mg of sample in a peeled aluminum dish and perform TGA analysis using a TA thermogravimetric analyzer. See the table below for specific parameters.
[0269] TGA parameters
[0270] DSC detection method:
[0271] Weigh 2-5 mg of sample into an aluminum pan, press the matching perforated cap onto the pan, and perform DSC analysis using a TA differential scanning calorimeter. See the table below for specific parameters.
[0272] DSC parameters
[0273] Example 1: Synthesis of 2-amino-3-((dimethylamino)methyl)-N-((1,2,3,5,6,7-hexahydro-s-indarsen-4-yl)carbamoyl)benzenesulfonamide
[0274] Synthesis route:
[0275] Step 1: Synthesis of 1-(3-bromo-2-nitrophenyl)-N,N-dimethylmethylamine (compound a)
[0276] 600 mg of 3-bromo-2-nitrobenzaldehyde was weighed into a 100 mL single-necked flask, and then 25 mL of DCM was added. Dimethylamine (THF, 2 M) (2 eq.) and HOAc (0.2 eq.) were added with stirring, and the mixture was stirred at room temperature for 2 h. After 2 h, NaBH(OAc)3 (3 eq.) was added in portions at room temperature, and stirring was continued at room temperature for another 2 h. LCMS showed the formation of the target compound.
[0277] Post-processing and purification: The reaction solution was poured into an appropriate amount of ice water and extracted twice with an extractant of DCM:MeOH = 10:1 (v / v) (30 mL). The organic phases were combined, washed with saturated brine, dried and rotary evaporated. The crude product of the target compound was obtained by rapid column chromatography (DCM / MeOH = 10:1 (v / v)) as a yellow oily liquid, 520 mg.
[0278] Step 2: Synthesis of 1-(3-(benzylmercapto)-2-nitrophenyl)-N,N-dimethylmethylamine (compound b)
[0279] 1-(3-bromo-2-nitrophenyl)-N,N-dimethylmethylamine (520 mg) was weighed into a 40 mL microwave tube. Toluene (12 mL), benzyl mercaptan (2 eq.), DIEA (3 eq.), Pd2(dba)3 (0.1 eq.), and Xantphos (0.2 eq.) were added under a nitrogen atmosphere. The mixture was heated to 115 °C and reacted for 12 h. LCMS showed that the target compound was formed.
[0280] Post-processing and purification: The reaction solution was mixed with silica gel and then rotary evaporated. After rapid column chromatography (DCM / MeOH = 10:1 (v / v)), 420 mg of the crude product of the target compound was obtained as a yellow oily liquid.
[0281] Step 3: Synthesis of 3-((dimethylamino)methyl)-2-nitrobenzenesulfonamide (compound c)
[0282] Measure 1.0 mL of 6M HCl into a 50 mL single-necked flask, add 15 mL of MeCN, stir and cool to 0 °C, then add 4 eq. of NCS; dissolve 420 mg of 1-(3-(benzylmercapto)-2-nitrophenyl)-N,N-dimethylmethylamine in 10 mL of MeCN and add it dropwise to the above single-necked flask at 0 °C, stirring for 0.5 h. Separately prepare a 100 mL single-necked flask, add 35 mL of NH4OH, and add the mixed solution from the above single-necked flask dropwise to the NH4OH while stirring at room temperature for 0.5 h. LC-MS confirms the formation of the target compound.
[0283] Post-processing and purification: MeCN was removed by rotary evaporation, and the product was extracted twice with DCM:MeOH = 10:1 (v / v) (50 mL). After drying and concentration under reduced pressure, 0.5 g of the crude yellow oily product of the target compound was obtained.
[0284] Step 4: Synthesis of 3-((dimethylamino)methyl)-N-((1,2,3,5,6,7-hexahydro-s-indarsen-4-yl)carbamoyl)-2-nitrobenzenesulfonamide (compound e)
[0285] 300 mg of 1,2,3,5,6,7-hexahydro-s-indargen-4-amine (compound d) was weighed into a 40 mL single-necked flask. DCM (10 mL) and DIEA (5 eq.) were added, and triphosgene (0.4 eq.) was added in portions with stirring at room temperature. The mixture was heated to 50 °C and reacted for 1 h. 500 mg of crude 3-((dimethylamino)methyl)-2-nitrobenzenesulfonamide was dissolved in DCM (5 mL) and DIEA (3 eq.), heated to 50 °C, and then added dropwise to the above single-necked flask. The mixture was reacted at 50 °C for 2 h, and LC-MS confirmed the formation of the target compound.
[0286] Post-processing and purification: The reaction solution was directly mixed with silica gel and subjected to rapid column chromatography (DCM / MeOH = 10:1 (v / v)) to obtain crude product. The crude product was purified by rapid column chromatography (0.05% NH4HCO3 aqueous solution) and lyophilized to obtain 280 mg of white solid of the target compound.
[0287] MS:459[M+H] + ; 1H NMR (400MHz, DMSO-d6) δ10.53(s,1H),8.09(d,J=7.6Hz,1H),7.94(s,1H),7.85(d,J=7.2Hz,1H),7.76(t,J=7.6 Hz,1H),6.90(s,1H),3.64(s,2H),2.78(t,J=7.2Hz,4H),2.60(t,J=7.0Hz,4H),2.27(s,6H),1.98-1.86(m,4H).
[0288] Step 5: Synthesis of 2-amino-3-((dimethylamino)methyl)-N-((1,2,3,5,6,7-hexahydro-s-indarin-4-yl)carbamoyl)benzenesulfonamide
[0289] Weigh 280 mg of 3-((dimethylamino)methyl)-N-((1,2,3,5,6,7-hexahydro-s-indarsen-4-yl)carbamoyl)-2-nitrobenzenesulfonamide into a 40 mL single-necked flask, add 6 mL of EtOH and 3 mL of H2O, and add 15 eq. of zinc powder and 5 eq. of ammonium chloride while stirring at room temperature. After the addition is complete, raise the reaction temperature to 60 °C and react for 4 h. LCMS confirmed the formation of the target compound and the complete reaction of the starting materials.
[0290] Post-processing and purification: The reaction solution was filtered with diatomaceous earth, and the filter cake was washed with 100 mL of DCM / MeOH = 10 / 1 (v / v). The filtrate was concentrated, and when a small amount of filtrate remained, the crude product was passed through a fast column chromatography. The crude product was purified by fast column chromatography (0.05% NH4HCO3) and lyophilized to obtain 210 mg of the target compound as a white solid.
[0291] MS:429[M+H] + : 1 H NMR (400MHz, DMSO-d6) δ8.00(s,1H),7.63(d,J=8.4,Hz,1H),7.24(d,J=6.8Hz,1H),6.90(s,1H),6.62(t, J=7.6Hz,1H),3.56(s,2H),2.76(t,J=7.4Hz,4H),2.52(t,J=7.4Hz,4H),2.24(s,6H),1.95-1.86(m,4H).
[0292] Example 2: Salt formation procedure for sodium 2-amino-3-((dimethylamino)methyl)-N-((1,2,3,5,6,7-hexahydro-s-indarsen-4-yl)carbamoyl)benzenesulfonamide:
[0293] Add 4.2 L of water to a single-necked flask, and add 46 g of the product from Example 1 while stirring. Add 1.3 L of 0.1 M NaOH while stirring at room temperature. At this point, the pH of the solution in the single-necked flask is approximately 11, and a large amount of solid dissolves, but a small amount of insoluble solid remains. Filter to obtain filter cake A. Add 1.4 L of saturated sodium chloride to the filtrate while stirring until a large amount of solid precipitates. Then add another 1.4 L of saturated sodium chloride solution, stir for 15 min in an ice-water bath, filter to obtain filter cake B, and wash with 1% NaCl (80 mL × 3) solution. The purity after HPLC purification is 99.1%. Freeze-dry to obtain 33.2 g of product B.
[0294] After repeating the salting process of filter cake A, the purity of the product after preparative-HPLC purification was 99.1%, and 3.8g of product A was obtained by freeze-drying.
[0295] A total of 37g of salt product was obtained from products A and B.
[0296] Example 3: Salt formation procedure for potassium 2-amino-3-((dimethylamino)methyl)-N-((1,2,3,5,6,7-hexahydro-s-indarsen-4-yl)carbamoyl)benzenesulfonamide:
[0297] 22 mL of water was added to a 100 mL single-necked flask, and 300 mg of the product from Example 1 was added with stirring. 8.5 mL of 0.1 M KOH was added with stirring at room temperature. At this point, the pH of the solution in the single-necked flask was approximately 11, and a large amount of solid dissolved, but a trace amount of insoluble solid remained. The solution was filtered, and a large amount of solid precipitated when 5 mL of saturated potassium chloride was added to the filtrate with stirring. Another 5 mL of saturated potassium chloride solution was added, and the mixture was stirred in an ice-water bath for 15 min. The solution was filtered, and the filter cake was washed with 3 mL of 1% KCl solution and purified by preparative HPLC to a purity greater than 98%. 220 mg of white solid product was obtained by freeze-drying.
[0298] Example 4: Salt formation of sodium 2-amino-3-((dimethylamino)methyl)-N-((1,2,3,5,6,7-hexahydro-s-indarsen-4-yl)carbamoyl)benzenesulfonamide (low crystallinity sodium salt):
[0299] Add 4.2 L of water to a single-necked flask, and add 46 g of the product from Example 1 while stirring. Add 1.3 L of 0.1 M NaOH while stirring at room temperature. At this point, the pH of the solution in the single-necked flask is approximately 11 and a large amount of solid dissolves. Filter the solution, and add 1.4 L of saturated sodium chloride to the filtrate while stirring until a large amount of solid precipitates. Then add another 1.4 L of saturated sodium chloride solution, stir for 15 min in an ice-water bath, filter, and wash the filter cake with a 1% NaCl solution (80 mL × 3). After preparative-HPLC purification, freeze-dry to obtain 33.2 g of low-crystallinity sodium salt product.
[0300] Example 5: Preparation of sodium salt of 2-amino-3-((dimethylamino)methyl)-N-((1,2,3,5,6,7-hexahydro-s-indarsen-4-yl)carbamoyl)benzenesulfonamide (crystal form 2):
[0301] Method A: 720 mL of water was added to a 1 L single-necked flask. 7.9 g of the product from Example 1 was added with stirring. 220 mL of 0.1 M NaOH (pH ≈ 11) was added with stirring at room temperature. The mixture was filtered. When 120 mL of saturated sodium chloride was added to the filtrate with stirring, a large amount of solid precipitated. Another 120 mL of saturated sodium chloride solution was added. The mixture was stirred in an ice-water bath for 15 min. The mixture was filtered, and the filter cake was washed with 1% NaCl solution (30 mL × 3). After drying at room temperature, 6.0 g of white solid was obtained. This solid was identified as the trihydrate crystal form 2 of the sodium salt of compound I.
[0302] Method B: The sodium salt with low crystallinity (100 mg) from Example 4 was placed in a stability chamber at 25°C and 92.5% RH for 24 hours to obtain crystal form 2.
[0303] The X-ray powder diffraction pattern of crystal form 2 using Cu-Kα radiation is shown in Figure 7, the DSC curve of crystal form 2 is shown in Figure 8, and the TGA curve of crystal form 2 is shown in Figure 9.
[0304] Example 6: Preparation of sodium salt of 2-amino-3-((dimethylamino)methyl)-N-((1,2,3,5,6,7-hexahydro-s-indarsen-4-yl)carbamoyl)benzenesulfonamide (crystal form 3):
[0305] The sodium salt with low crystallinity (15 mg) from Example 4 was slurried in 300 μL of acetone / n-heptane (v / v = 1 / 9) at room temperature for 24 hours to obtain crystal form 3.
[0306] The X-ray powder diffraction pattern of crystal form 3 under Cu-Kα radiation is shown in Figure 10, the DSC curve of crystal form 3 is shown in Figure 11, and the TGA curve of crystal form 3 is shown in Figure 12.
[0307] Example 7: Preparation of sodium salt of 2-amino-3-((dimethylamino)methyl)-N-((1,2,3,5,6,7-hexahydro-s-indarsen-4-yl)carbamoyl)benzenesulfonamide (crystal form 4):
[0308] The sodium salt with low crystallinity (30 mg) from Example 4 was slurried in 300 μL of isopropanol at room temperature for 24 hours to obtain crystal form 4.
[0309] The X-ray powder diffraction pattern of crystal form 4 using Cu-Ka radiation is shown in Figure 13, the DSC curve of crystal form 4 is shown in Figure 14, and the TGA curve of crystal form 4 is shown in Figure 15.
[0310] Example 8: Preparation of sodium salt of 2-amino-3-((dimethylamino)methyl)-N-((1,2,3,5,6,7-hexahydro-s-indarsen-4-yl)carbamoyl)benzenesulfonamide (crystal form 5):
[0311] The sodium salt with low crystallinity (100 mg) from Example 4 was slurried in 2 mL of acetone at room temperature for 24 hours to obtain crystal form 5.
[0312] The X-ray powder diffraction pattern of crystal form 5 using Cu-Ka radiation is shown in Figure 16, the DSC curve of crystal form 5 is shown in Figure 17, and the TGA curve of crystal form 5 is shown in Figure 18.
[0313] test:
[0314] 1. Solubility Experiment
[0315] The solubility of the compounds in Example 1 of this application using different solvents and the solubility of the salts in Examples 2-3 are shown in Table 1 below.
[0316] Table 1 Note: All solvent concentrations are mass percentages.
[0317] 1) Sample preparation method:
[0318] 01: Accurately weigh 1 mg of the unsalted compound, add 500 μL of 10% hydroxypropyl betacyclodextrin aqueous solution, sonicate for 10 min to dissolve, filter with a 0.22 μm syringe filter, and take the filtrate to detect the content;
[0319] 02: Accurately weigh 1 mg of the unsalted compound, add 500 μL of 5% SDS aqueous solution, sonicate for 10 min to dissolve it, filter with a 0.22 μm syringe filter, and take the filtrate to detect the content;
[0320] 03: Accurately weigh 1 mg of the unsalted compound, add 500 μL of 1% polysorbate-80 (Tween-80) aqueous solution, sonicate for 10 min to dissolve, filter with a 0.22 μm syringe filter, and take the filtrate to detect the content;
[0321] 04: Accurately weigh 1 mg of the unsalted compound, add 500 μL of 0.5% HPMC aqueous solution, sonicate for 10 min to dissolve, filter with a 0.22 μm syringe filter, and take the filtrate to detect the content;
[0322] 05: Accurately weigh 1 mg of the unsalted compound, add 500 μL of 0.5% MC aqueous solution, sonicate for 10 min to dissolve, filter with a 0.22 μm syringe filter, and take the filtrate to detect the content;
[0323] 06: Accurately weigh 1 mg of the unsalted compound, add 500 μL of 0.5% TPGS aqueous solution, sonicate for 10 min to dissolve, filter with a 0.22 μm syringe filter, and take the filtrate to detect the content;
[0324] 07: Accurately weigh 1 mg of the unsalted compound, add 500 μL of 5% octanoic acid-capric acid-polyethylene glycol glycerol aqueous solution, sonicate for 10 min to dissolve it, filter with a 0.22 μm syringe filter, and take the filtrate to detect the content;
[0325] 08: Accurately weigh 1 mg of the unsalted compound, add 500 μL of 5% polyoxyethylene RH40 hydrogenated castor oil aqueous solution, sonicate for 10 min to dissolve it, filter with a 0.22 μm syringe filter, and take the filtrate to detect the content;
[0326] 09: Accurately weigh 1 mg of the unsalted compound, add 500 μL of a 5% aqueous solution of EL35 hydrogenated castor oil, sonicate for 10 min to dissolve it, filter with a 0.22 μm syringe filter, and take the filtrate to test the content;
[0327] 10: Accurately weigh 15 mg of the unsalted compound, add 500 μL of 15% propylene glycol aqueous solution, sonicate for 10 min to dissolve, filter with a 0.22 μm syringe filter, and dilute the filtrate 20 times to detect the content;
[0328] 11: Accurately weigh 5 mg of the unsalted compound, add 500 μL of purified water, sonicate for 10 min to dissolve it, filter with a 0.22 μm syringe filter, and dilute the filtrate 5 times to detect the content;
[0329] 12: Accurately weigh 5 mg of the sodium salt of the compound, add 500 μL of purified water, sonicate for 10 min to dissolve it, filter with a 0.22 μm syringe filter, and dilute the filtrate 5 times to detect the content;
[0330] 13: Accurately weigh 5 mg of potassium salt of the compound, add 500 μL of purified water, sonicate for 10 min to dissolve it, filter with a 0.22 μm syringe filter, and dilute the filtrate 5 times to detect the content.
[0331] 2) Content determination method:
[0332] Instrument model: Agilent 1260
[0333] Chromatographic column: Poroshell 120SB-C18 2.7μm 4.6*100mm
[0334] Gradient: 10-100% B; Flow rate: 2 mL / min (0-10 min)
[0335] Column temperature: 35℃; injection volume: 10μL; detection wavelength: 220nm
[0336] Mobile phase A: 0.05% TFA - 2% acetonitrile (v / v)
[0337] Mobile phase B: 0.05% TFA - 90% acetonitrile (v / v)
[0338] Concentration of reference solution: 1 mg / mL
[0339] The content determination results are entered into Table 1 above in the form of solubility.
[0340] 2. Stability test of sodium salt of compound
[0341] The stability of the sodium salts in Example 2 with different properties is shown in Table 2 below.
[0342] Table 2
[0343] 1) Sample preparation:
[0344] Powder: Accurately weigh 1 mg of sodium salt of compound 2 from Example 2, put it into small centrifuge tubes, and divide it into 6 portions: place 3 portions in a 40℃ oven and 3 portions at room temperature. Dissolve the powder in 1 mL of purified water before testing.
[0345] Aqueous solution: Accurately weigh 1 mg of sodium salt of compound 2 from Example 2, put it into a small centrifuge tube, add 1 mL of purified water, shake to dissolve, and make 6 portions in total: place 3 portions in a 40°C incubator and 3 portions at room temperature;
[0346] CMC (carboxymethyl cellulose) solution: Accurately weigh 1 mg of sodium salt of compound 2 from Example 2, put it into a small centrifuge tube, add 1 mL of 1% CMC solution, shake to dissolve, make 6 portions in total: place 3 portions in a 40℃ incubator and 3 portions at room temperature.
[0347] 2) Purity testing methods:
[0348] Detection method: HPLC (area normalization method)
[0349] Chromatographic column: Poroshell 120SB-C18 2.7μm 4.6*100mm
[0350] Column temperature: 35℃
[0351] Detection wavelength: 220nm
[0352] Injection concentration: 1 mg / mL
[0353] Injection volume: 5 μL
[0354] Mobile phase A: 0.05% TFA - 2% acetonitrile (v / v)
[0355] Mobile phase B: 0.05% TFA - 90% acetonitrile (v / v)
[0356] Gradient: 10-100-10%B 0-10-12min
[0357] Flow rate: 2 mL / min;
[0358] The purity test results are shown in Table 2 above.
[0359] 3. Study on water activity of crystals
[0360] Crystal forms 2, 3, and 5 were competitively pulped in acetone solvents with different water activities. After stirring at room temperature for one day, samples were collected, filtered, and the wet solids were analyzed by XRPD. Crystal form 3 was not obtained during the competitive pulping process. Crystal form 2 was the stable crystal form when the water activity (aw.) ≥ 0.50, and crystal form 5 was the stable crystal form when the water activity (aw.) ≤ 0.43. The results are shown in Table 3 below.
[0361] Table 3. Water activity tests for crystal forms 2, 3, and 5.
[0362] 4. Crystal stability test
[0363] Crystal form 2 (batch number: 70108-050A1) and crystal form 5 (batch number: 70108-050A3) were placed in constant temperature and humidity chambers at 25℃ / 92.5% RH (open), 40℃ / 75% RH (open), and 60℃ (closed). Samples were collected on day 8 for XRPD and HPLC analysis. Crystal form 2 remained unchanged under all conditions. Crystal form 5 transformed into crystal form 2 under high humidity and 92.5% RH, while remaining unchanged under other conditions. The results are shown in Table 4 below.
[0364] Table 4. Results of stability studies for crystal forms 2 and 5
[0365] 5. Biological evaluation of compounds
[0366] Since the biological effects of compounds of formula I after salt formation are usually unchanged, compounds of formula I are used as an example for biological experiments.
[0367] Experimental Example 1: Inhibition curve of compound on activation of the classical NLRP3 pathway in mouse cell line J774A.1
[0368] J774A.1 cells were divided into groups of 1.0 × 10⁻⁶. 6 Cells were seeded at a density of 300 μL / mL in 48-well plates; subsequently, NLRP3 was activated with LPS+ATP (or Nigin), where:
[0369] The cell culture medium consisted of: DMEM (brand: Gibco, reference number: C12430500) + 10% fetal bovine serum (brand: Gibco, reference number: 10099-141) + 1% sodium pyruvate (brand: Gibco, reference number: 11360-070) + 1% penicillin-streptomycin mixture (brand: Solarbio, reference number: P1400);
[0370] J774A.1 mouse mononuclear macrophage cell line was purchased from the Cell Resource Center of the Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (Resource No. 1101MOU-PUMC000222);
[0371] LPS was purchased from Sigma, item number: L2654;
[0372] ATP was purchased from Sigma, item number: A2383;
[0373] Nig was purchased from Shanghai Yuanye Biotechnology, product number: S45490.
[0374] Experimental groups: negative control group, LPS-only control group, LPS combined with ATP / Nig positive control group, and experimental groups of compounds from different concentrations (concentration range: 0.00128-20 μM, 5-fold dilution) of the examples.
[0375] After J774A.1 cells adhered to the plate, the culture medium was changed: all groups except the negative control group had their culture medium completely replaced with cell culture medium containing 1 μg / mL LPS, while the negative control group had its culture medium replaced with cell culture medium; then, they were incubated overnight. After 18 hours, the culture medium was changed again: the culture medium for the experimental groups containing the compounds in the examples was completely replaced with culture medium containing different concentrations of the compounds; the negative control group, the LPS-only control group, and the LPS combined with ATP / Nig positive control group were replaced with cell culture medium. After 1 hour, the culture medium for the LPS combined with ATP / Nig positive control group and the experimental groups containing different concentrations of the compounds in the examples was completely replaced with cell culture medium containing 5 mM ATP or 10 μM Nig. After 1 hour, the cell supernatant was collected for IL-1β detection.
[0376] Experimental results
[0377] Because LPS+ATP activation of NLRP3 releases mature IL-1β, and this release can be inhibited by NLRP3 inhibitors, the relative change in IL-1β release directly reflects the inhibitory effect of NLRP3. Different concentrations of compounds exhibit different inhibitory strengths, allowing for the construction of inhibition curves, which can then be analyzed using IC50. 50 The inhibitory effect of the compounds was evaluated. The results are shown in Table 5.
[0378] Table 5 (IC50 in J774A.1 cells under LPS+ATP activation model) 50 (Measurement results)
[0379] The results showed that the IC50 of the compound in Example 1 was... 50 The IC is 113.9nm, MCC950. 50 It is 687 nM (Table 5).
[0380] Experimental Example 2: Inhibition curve of classical NLRP3 pathway activation in human cell line THP-1
[0381] THP-1 cells were 1.0 × 10⁻⁶ 6 Cells were seeded at a density of 100 μL per well in 96-well plates. PMA-induced differentiation and cell rest were then performed, followed by NLRP3 activation via LPS or Pam3CSK4+Nig.
[0382] The cell culture medium consisted of: 1640 medium (brand: Gibco, reference number: C11875500BT) + 10% fetal bovine serum (brand: Gibco, reference number: 11360-070) + 1% penicillin-streptomycin mixture (brand: Solarbio, reference number: P1400).
[0383] The THP-1 human acute monocytic leukemia cell line was purchased from the Cell Resource Center of the Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (Resource No. 1101HUM-PUMC000057).
[0384] LPS was purchased from Sigma, item number: L2654.
[0385] PMA was purchased from Sigma, item number: P1585.
[0386] Nig was purchased from Shanghai Yuanye Biotechnology, product number: S45490.
[0387] The Pam3CSK4 was purchased from MedChemExpress, item number: HY-P1180A.
[0388] Experimental groups: negative control group, LPS control group incubated alone, LPS or Pam3CSK4 combined with Nig positive control group, and experimental groups of different concentrations (concentration range: 0.00128-20 μM, 5-fold dilution) of the compound from the example.
[0389] While plating THP-1 cells, 100 ng / mL PMA was added. After incubation for 24 h, the cells were washed three times with PBS, the culture medium was changed, and the cells were allowed to rest for 24 h. Then, the culture medium was completely changed and the cells were incubated overnight with 1 μg / mL LPS or 1 μg / mL Pam3CSK4. The next day, the culture medium was completely changed for the wells with added LPS, and then the cells were incubated with different concentrations of the specified compound for 1 h. Then, 5 μM Nig was added and the cells were incubated for 45 min. The cell supernatant was then collected for IL-1β detection and Caspase-1 activity detection.
[0390] Experimental results
[0391] Because LPS or Pam3CSK4+Nig activates NLRP3 and releases mature IL-1β, and this release can be inhibited by NLRP3 inhibitors, the relative change in IL-1β release directly reflects the inhibitory effect of NLRP3. Different concentrations of compounds have different inhibitory strengths, and inhibition curves can be constructed accordingly. The inhibitory effect can then be analyzed using IC50. 50 The inhibitory effects of the compounds were evaluated. The results are shown in Tables 6 and 7.
[0392] Table 6 (IC50 in THP-1 cells under LPS+Nig activation model) 50 (Measurement results)
[0393] Table 7 (IC under Pam3CSK4+Nig activation model) 50 (Measurement results)
[0394] The results showed that the IC50 of the compound in Example 1 under the LPS+Nig activated NLRP3 model was [value missing]. 50 The concentration was 278.0 nM for the compound and 315.0 nM for the compound MCC950 (Table 6). IC50 of the compound in Example 1 against IL-1β under the Pam3CSK4+Nig activated NLRP3 model. 50 The concentration was 43.1 nM for Compound 1 and 208.5 nM for MCC950 (Table 7); IC50 of Compound 1 against Caspase-1 50 The value is 18.9 nM, while that of MCC950 is 101.5 nM (Table 7).
[0395] Experiment Example 3: Plotting the activation and inhibition curves of the classical NLRP3 pathway in whole blood of healthy individuals.
[0396] 10 mL of human whole blood was aseptically collected intravenously and spread into a 96-well plate, 198 μL per well. Then, 2 μL of a 100× (here, 100 times the working concentration) gradient dilution of the example compound was added to prepare a final concentration gradient (5-fold dilution) ranging from 0.00128 to 500 μM. Immediately afterward, 10 μL of 21 μg / mL LPS gradient dilution was added. After 3 hours, 5 μM Nigerian styracin (or 1 mM ATP) was added. After 1 hour of stimulation, whole blood was collected, and the supernatant was collected by centrifugation. The IL-1β in the sample supernatant was then detected by ELISA.
[0397] Heparin sodium injection was purchased from Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd.
[0398] LPS was purchased from Sigma, item number: L2654;
[0399] ATP was purchased from Sigma, item number: A2383;
[0400] Nig, a styramine, was purchased from Shanghai Yuanye Biotechnology Co., Ltd., product number: S45490.
[0401] The human IL-1β ELISA kit was purchased from Thermo Invitrogen, catalog number: 88-7261-88.
[0402] Experimental groups: negative control group, LPS-only control group, LPS combined with Nig / ATP positive control group, and 1 μM compound experimental group.
[0403] Add the anticoagulant sodium heparin to a 50 mL centrifuge tube beforehand, and add 10 mL of aseptically collected human whole blood from a vein. Plate the collected whole blood directly into a 96-well plate (198 μL per well), then add 2 μL of a serially diluted 100× compound of the example at the specified concentration, followed immediately by 10 μL of a serially diluted 21 μg / mL LPS solution. After 3 hours, add a working concentration of 5 μM Nig / 1 mM ATP. Stimulate for 1 hour, then collect the whole blood, centrifuge to collect the supernatant, and detect IL-1β in the supernatant using ELISA.
[0404] Experimental results
[0405] Because classical activation of NLRP3 releases mature IL-1β, and this release can be inhibited by NLRP3 inhibitors, the relative change in IL-1β release directly reflects the inhibitory effect of NLRP3. Different concentrations of compounds exhibit different inhibitory strengths, allowing for the construction of inhibition curves and analysis using IC50. 50 The inhibitory effect of the compounds was evaluated. The results are shown in Table 8.
[0406] The results show that, in the model system of LPS + 5μM Nig, the IC of MCC950 is [missing information]. 50 The concentration was 3.22 μM; the concentration of the compound in Example 1 was 1.27 μM (Table 8).
[0407] Table 8 (IC50 in human whole blood LPS+Nig classical pathway activation model) 50 (Measurement results)
[0408] Experimental Example 4: LPS-induced sepsis model inhibits NLRP3 activation
[0409] Intraperitoneal injection of 20 mg / kg LPS can induce sepsis in C57BL / 6 mice and cause a significant increase in serum IL-1β after injection. The effects of early intraperitoneal injection of the compound on the increase of IL-1β and the survival rate of mice were studied.
[0410] LPS was purchased from Sigma, part number L2630;
[0411] Six- to eight-week-old male C57BL / 6J mice were purchased from the National Institutes for Food and Drug Control.
[0412] Experimental groups: spurious model group, model group, compound administration group, MCC950 administration group.
[0413] Mice were intraperitoneally injected with 30 mg / kg of the compound from the examples and MCC950. One hour later, the modeling group, the compound from the examples group, and the MCC950 group were intraperitoneally injected with 20 mg / kg LPS to induce the model. The sham modeling group was injected with the control solvent (physiological saline). Serum samples were collected from one batch of mice at 2.5 h and 4 h after modeling to analyze IL-1β levels. The survival rate of another batch of mice was determined after modeling.
[0414] Experimental results
[0415] The serum IL-1β levels at 2.5 h and 4 h post-modeling are shown in Figure 1(a) (5 mice per group), and the mouse survival rate statistics are shown in Figure 1(b) (10 mice per group). Statistical analysis showed that the IL-1β levels of MCC950 were not significantly different from those of the modeling group at 2.5 h (ns, P>0.05), but the difference was significant at 4 h (****, P<0.0001); the compound of Example 1 showed significant differences from the modeling group at both 2.5 h and 4 h (**, P<0.01, 2.5 h; ****, P<0.0001, 4 h). Regarding survival rate, the compound of Example 1 significantly improved the survival rate of mice compared to the modeling group (P<0.0001, ****), and the compound of Example 1 further significantly improved the survival rate compared to MCC950 (P<0.05, *).
[0416] Experimental Example 5: MSU-induced mouse peritonitis model - Compounds from the above examples inhibit NLRP3 activation
[0417] Intraperitoneal injection of LPS and monosodium urate crystals (MSU) in mice induces NLRP3 activation and releases large amounts of IL-1β. IL-1β release can be inhibited by pre-gavage administration of NLRP3 inhibitors.
[0418] LPS mice were purchased from Sigma (product number L2654). MSU mice were purchased from Bidex Pharmaceuticals (product number BD367417). Eight-week-old female C57BL / 6J mice were purchased from the National Institutes for Food and Drug Control.
[0419] The compound and MCC950 were administered orally via gavage. Two hours later, 1.25 μg of LPS was injected intraperitoneally. Two hours later, MSU was injected intraperitoneally. Ascites fluid was collected 30 minutes later, and then the IL-1β protein in the ascites fluid was detected.
[0420] Experimental groups: modeling group, compound administration group, MCC950 administration group.
[0421] Experimental results
[0422] The IL-1β levels in the ascites fluid are shown in Figure 2 (n=9-14 per group). Statistical analysis showed that, compared with the model group, the compound in Example 1 significantly inhibited the IL-1β level (**, P<0.01), while MCC950 showed only a trend toward inhibition (ns, P=0.06).
[0423] Experimental Example 6: Analysis of the pharmacokinetic properties of compounds in mice
[0424] C57 mice were intravenously administered the drug at a concentration of 5 mg / kg. Blood samples were collected from the eyes of mice at 1 min, 30 min, 1 h, and 2 h after drug administration. Plasma was collected after centrifugation at 3000 rpm for 10 min at 4°C. Acetonitrile was added at a plasma:acetonitrile ratio of 1:3 to precipitate proteins. After centrifugation, the supernatant was collected, filtered, and the compound concentration was determined by LC-MS (Agilent 1260-G6125, SIM mode). Additionally, 2 h after drug injection, the mice underwent cardiac perfusion, and their brains were harvested. The brain tissue was ground, centrifuged, and the supernatant was collected. Acetonitrile was added at a supernatant:acetonitrile ratio of 1:3 to precipitate proteins. After centrifugation, the supernatant was collected, filtered, and the compound concentration was determined by LC-MS (Agilent 1260-G6125, SIM mode).
[0425] Experimental groups: solvent control group, drug administration group.
[0426] Experimental results
[0427] The plasma pharmacokinetic analysis results of the compound and control drug MCC950 in Example 1 are shown in Figures 3 and 4.
[0428] The results showed that the half-life of the compound in Example 1 was 139 min, the area under the curve from 1 to 120 min was 14664 ng·h / mL, the brain drug concentration at 120 min was 242 ng / mL, and the Kpuu (brain-plasma unbound partition ratio) was 0.25.
[0429] The half-life of the control drug MCC950 in the parallel test was 77 min, the area under the curve from 1 to 120 min was 29642 ng·h / mL, and the brain drug concentration at 120 min was 0 ng / mL (below the limit of detection).
[0430] Experimental Example 7: Analysis of the drug metabolic properties of the compound in rats
[0431] SD rats were intravenously administered the drug at a concentration of 2.5 mg / kg. Blood samples were collected at 1 min, 30 min, 1 h, 2 h, 4 h, 6 h, and 24 h. Plasma was collected after centrifugation at 3000 rpm for 10 min at 4 °C. Acetonitrile was added at a plasma:acetonitrile volume ratio of 1:3 to precipitate the protein. After centrifugation, the supernatant was collected, filtered, and the compound concentration was detected by LC-MS (Agilent 1260-G6125, SIM mode).
[0432] Experimental groups: solvent control group, drug administration group.
[0433] Experimental results
[0434] The plasma pharmacokinetic analysis results of the compound and control drug MCC950 in Example 1 are shown in Figures 5 and 6.
[0435] The results showed that the half-life of the compound in Example 1 was 231 min, and the area under the curve from 1 to 1440 min was 56453 ng·h / mL.
[0436] The half-life of the control drug MCC950 in the parallel test was 16 min, and the area under the curve from 1 to 1440 min was 4376 ng·h / mL.
[0437] Experimental Example 8: Cardiotoxicity Evaluation of Compounds from Examples - Determination of hERG Inhibition
[0438] 8.1 Cell Culture
[0439] In this experiment, the HEK-293 cell line stably expressing hERG potassium channels was used. These hERG potassium channel cells were purchased from Creacell (catalog number: A-0320). The cell culture method is as follows:
[0440] HEK-293 cell lines stably expressing hERG potassium channels were cultured in DMEM medium (hereinafter referred to as complete medium) containing 10% fetal bovine serum (brand: Gibco, reference number: 10099-141) and 0.8 mg / mL G418 (geneticom, ST081, Beyotime) at a temperature of 37°C and a carbon dioxide concentration of 5%.
[0441] Cell passage: Remove the old culture medium and wash once with PBS, then add 1 mL TrypLE TMIncubate with Express solution (Gibco 12604-021) at 37°C for approximately 1 minute. Once cells detach from the bottom of the dish, add approximately 5 mL of preheated (37°C) complete culture medium. Gently pipette the cell suspension to separate aggregated cells. Transfer the cell suspension to sterile centrifuge tubes and centrifuge at 1000 rpm for 5 minutes to collect cells. For expansion or maintenance culture, seed cells into 10 cm cell culture dishes at a density of 6 × 10⁶ cells per dish. 5 Cells (final volume: 5 mL).
[0442] To maintain the electrophysiological activity of cells, the cell density must not exceed 80%.
[0443] Before patch-clamp detection, cells were treated with TrypLE. TM Cells were isolated using Express (Gibco12604-021) culture medium to terminate digestion, centrifuged, resuspended, and counted. The cell density was adjusted to 2-3 x 10⁶ cells / year. 6 Cells / mL, then gently mix the cells on a balanced shaker for 15-20 minutes at room temperature before instrumentation.
[0444] 8.2 Electrophysiological Recording
[0445] 8.2.1 Record the liquids used
[0446] Extracellular fluid: K-007-1
[0447] 140mM NaCl, 3.5mM KCl, 1mM MgCl2·6H2O, 2mM CaCl2·2H2O, 10mM D-Glucose, 10mM HEPES, 1.25mM NaH2PO4·2H2O, with NaOH adjusted to pH 7.4.
[0448] Intracellular fluid: K-002-2
[0449] 20mM KCl, 115mM K-Aspartate, 1mM MgCl2·6H2O, 5mM EGTA, 10mM HEPES, 2mM Na2-ATP, KOH adjust pH=7.2.
[0450] Extracellular fluid was stored for one week. Intracellular fluid, after preparation, was aliquoted into 10 mL tubes and stored at -20°C. Freshly thawed intracellular fluid was used daily for experiments. All intracellular fluid was used within one week. After one week, the old intracellular fluid was discarded and freshly prepared.
[0451] 8.2.2 Patch clamp testing
[0452] This experiment used a fully automated patch-clamp QPatch 48X (Sophion) device for electrophysiological testing.
[0453] First, the prepared cells are placed on a centrifuge in the Qpatch workbench and washed using multiple centrifugation / resuspension methods to replace the cell culture medium with extracellular fluid. An MTP-96 plate is removed and placed in the MTP source position. The QPlate chip is removed and placed in the QPlate source position. The robotic arm scans the barcodes on the MTP-96 plate and the QPlate chip and picks them up to the measurement station. Intracellular fluid and extracellular fluid are aspirated from the liquid pools and added to the intracellular fluid pool and cell and compound pool of the QPlate chip, respectively. At the measurement station, all measurement sites on the QPlate undergo initial quality control. The quality control process includes aspirating the cell suspension from the centrifuge's cell container and positioning the cells onto the chip wells using a pressure controller to establish a high-resistance seal, forming a whole-cell recording mode. Once a stable control current baseline is obtained, the test substances are sequentially aspirated from the MTP-96 plate according to their concentration and applied to the cells.
[0454] The voltage stimulation protocol for whole-cell patch-clamp recording of hERG currents is as follows: After whole-cell occlusion, the cell membrane voltage is clamped at -80 mV. The clamping voltage is depolarized from -80 mV to -50 mV and maintained for 0.5 s (as a leakage current detection), then stepped to 30 mV and maintained for 2.5 s, and then rapidly restored to -50 mV and maintained for 4 s to excite the tail current of the hERG channel. Data is collected every 10 s to observe the effect of the drug on the hERG tail current. Experimental data are collected by a QPatch screening workstation and stored in a database server.
[0455] Each drug concentration was administered twice, with a time interval of at least 5 minutes. The current detected in each cell in an external solution free of the compound served as its control group, and two cells were independently measured repeatedly. All electrophysiological experiments were performed at room temperature.
[0456] 8.3 Data Quality Standards
[0457] The following criteria are used to determine whether data is acceptable:
[0458] (1) Sealing resistance > 1 GΩ
[0459] (2) Initial connection resistance <15MΩ
[0460] (3) The resistance connection ends at <15MΩ
[0461] (4) Peak initial tail current > 200pA
[0462] (5) The peak value of the initial tail current is greater than the peak value of the activation current.
[0463] (6) The tail current does not show obvious spontaneous decay.
[0464] (7) No significant leakage current at a membrane potential of -80mV (no significant absolute value of the maximum leakage current peak).
[0465] 8.4 Data Analysis
[0466] The second dose of the two administrations was used for data analysis. The average of the last three data points of the current drug concentration before the next administration concentration was taken to represent the current value after the effect of that concentration. The current value representing each drug concentration and the reference current value used as a blank control were normalized, and then the inhibition rate corresponding to each drug concentration was calculated.
[0467] Experimental results
[0468] The hERG inhibition rates of the compound in Example 1 at 1 μM and 10 μM were tested using the above method, and compared with those of the antiarrhythmic drug dofetilide. The IC50 of dofetilide was determined. 50 The inhibition rate of the compound in Example 1 was 0.016 μM, and the results are shown in Table 9 below.
[0469] Table 9
[0470] The above results demonstrate that the embodiments of this application have good safety in terms of hERG inhibition-related toxicity.
[0471] 6. Pharmacokinetic studies of crystals:
[0472] C57 mice were administered the drug via gavage at a dose of 10 mg / kg. Blood samples were collected from the eyes of the mice at 10 min, 30 min, 2 h, 6 h, and 24 h after drug administration. Plasma was then collected by centrifugation at 3000 rpm for 10 min at 4 °C. Acetonitrile was added at a plasma:acetonitrile ratio of 1:3 to precipitate proteins. After centrifugation, the supernatant was collected, filtered, and the compound concentration was determined by LC-MS (Agilent 1260-G6125, SIM mode).
[0473] Experimental results
[0474] The plasma pharmacokinetic analysis results of the compound (crystal form 2) prepared by method A in Example 5 are shown in Figure 19. The results show that the area under the curve (AUC) of compound (crystal form 2) in Example 5 (1-24h) is 249222 ng·h / ml, and the peak plasma concentration (Cmax) is 22606 ng / ml.
[0475] The plasma pharmacokinetic analysis results of the control drug AZD4144 in parallel tests are shown in Figure 20. The results show that the area under the curve (AUC) of AZD4144 (amorphous) from 1 to 24 hours was 42117 ng·h / ml, and the peak plasma concentration (Cmax) was 2613 ng / ml.
[0476] 7. Biological evaluation of crystals:
[0477] Experimental content
[0478] 1) In a collagen-induced rheumatoid arthritis (CIA) model in female SD rats, an autoimmune response is induced, leading to progressive articular cartilage damage and ultimately severe cartilage degradation. Based on this, concomitant drug administration was used, and the effect of serum IgG1 levels on the model's morbidity was analyzed. Safranin-Fibrin staining of ankle joint tissue was used to observe whether IgG had a preventive effect on ankle cartilage damage in this model.
[0479] 2) Sodium iodoacetate (MIA) can induce osteoarthritis (OA) in male SD rats. By injecting MIA into the knee joint cavity of rats, chondrocyte metabolism is inhibited, leading to cartilage degeneration and subchondral bone remodeling, mimicking the pathological changes of human OA. Based on this, concomitant administration was used, and Safranin-Fix-Green staining of knee joint tissue was used to observe whether it has an inhibitory effect on the development of ankle joint bone injury in this model.
[0480] 7.1 The compound (crystal form 2) prepared by method A in Example 5 inhibited the onset of rheumatoid arthritis (CIA) and prevented cartilage damage.
[0481] Female SD rats were subcutaneously injected with 200 μl of emulsified type II collagen in two doses, seven days apart. The emulsification process involved mixing an equal volume of fetal bovine type II collagen with incomplete Freund's adjuvant. Following the first collagen injection, rats were administered oral gavage once daily with either the compound from Example 5 or the control drug indomethacin until day 28. Serum samples were collected on day 14 post-modeling to analyze the protein level of the pathogenesis-related marker IgG1. Knee joint tissue was harvested at the endpoint, fixed, decalcified, paraffin-embedded, sectioned, and stained with Safranin-Fix-Green. Cartilage damage was evaluated using a cartilage damage score.
[0482] Experimental groups: spurious model group, model group, compound administration group of Example 5, and control group.
[0483] Fetal bovine type II collagen, incomplete Freund's adjuvant, and IgG1 ELISA kits were purchased from Chondrex (catalog numbers 20021, 7002, and 20421T, respectively). Indomethacin was purchased from Shanghai Yuanye Biotechnology Co., Ltd. (catalog number S18048). The modified safranin O-fast green cartilage staining kit and EDTA decalcification solution were purchased from Beijing Solarbio Science & Technology Co., Ltd. (catalog numbers G1371 and E1171, respectively). Seven-week-old female SD rats were purchased from the National Institutes for Food and Drug Control (NIFDC).
[0484] Experimental results
[0485] The serum IgG1 level on the day of onset (day 14) after modeling is shown in Figure 21a (n=12-13 per group). Statistical analysis showed that the IgG1 level in the modeling group was significantly higher than that in the sham modeling group (**, P<0.01). Compared with the modeling group, the compound in Example 5 significantly inhibited the significant increase in IgG1 level induced by modeling (*, P=0.05), while indomethacin had no significant effect on IgG1 level compared with the modeling group (ns, P=0.55).
[0486] At the end of the modeling process (day 28), safranin-fast green staining was performed on unilateral knee joint tissues, and representative images of each group are shown in Figure 21b. The statistical results of cartilage damage scores are shown in Figure 22c (6 animals per group). The results showed that, compared to the sham model group, the cartilage damage in the model group was significantly increased (****, P<0.0001). Compared to the model group, the compound of Example 5 significantly inhibited the cartilage damage induced by the modeling process (***, P<0.001), while indomethacin, although inhibiting the cartilage damage induced by the modeling process (*, P<0.05), had a higher P-value and a higher mean score than the compound of Example 5.
[0487] Note: The average score for the indomethacin group was 1.83, the average score for the compound in Example 5 was 0.83, the average score for the model group was 3.16, and the average score for the sham surgery group was 0.16. The scoring range was 0-4 points, with 4 points representing the most severe damage and 0 points representing no damage.
[0488] Figure 21 shows that the compound of Example 5 has a protective effect against cartilage damage in a collagen-induced rheumatoid arthritis (CIA) model and regulates the expression of pathogenesis-related IgG1 protein.
[0489] 7.2 The compound (crystal form 2) prepared by method A in Example 5 inhibited the progression of bone injury in a model of osteoarthritis (MIA).
[0490] Male SD rats were injected unilaterally into the knee joint with 4 mg of sodium iodoacetate (MIA) to induce inhibition of chondrocyte metabolism, leading to cartilage degeneration and subchondral bone remodeling, mimicking the progressive development of clinical knee osteoarthritis. Following MIA injection, the rats were administered the drug once daily via gavage (as described in Example 5). On days 7 and 14 post-modeling, tissue samples from the affected knee joint were collected, fixed, and decalcified before paraffin embedding, sectioning, and safranin-fast green staining. The degree of bone damage was assessed using the Mankin scale.
[0491] Experimental groups: modeling group, compound administration group of Example 5.
[0492] Sodium iodoacetate (MIA) was purchased from MedChemExpress, catalog number hy-d849. The modified safranin O-fix green cartilage staining kit and EDTA decalcification solution were purchased from Beijing Solarbio Science & Technology Co., Ltd., catalog numbers G1371 and E1171, respectively. Seven-week-old female SD rats were purchased from the National Institutes for Food and Drug Control.
[0493] Experimental results
[0494] The representative images of the knee joint tissue stained with Safranin and Fast Green on days 7 and 14 post-modeling are shown in Figure 22a. The statistical results of cartilage damage scores are shown in Figure 22b (day 7, 4 animals per group; day 14, 8-11 animals per group). The results show that, compared with the modeling group (left bar charts of days 7 and 14 in Figure 22b), the compound of Example 5 (right bar charts of days 7 and 14 in Figure 22b) significantly inhibited the cartilage damage induced on day 7 (*, P<0.05) and day 14 (**, P<0.01) post-modeling.
[0495] Figure 22 shows that the compound of Example 5 inhibited the development of bone injury in a sodium iodoacetate (MIA)-induced osteoarthritis (OA) model.
[0496] In summary, compared with existing related technologies, the compounds, salts of the compounds, and crystal forms of the salts of this application have better cellular activity, better pharmacokinetic half-life and exposure, better blood-brain barrier permeability, and better efficacy in animal models.
[0497] Although the embodiments disclosed in this application are as described above, the content described is merely for the purpose of understanding this application and is not intended to limit this application. Any person skilled in the art to which this application pertains may make any modifications and changes in the form and details of the implementation without departing from the spirit and scope disclosed in this application; however, the scope of patent protection of this application shall still be determined by the scope defined in the appended claims.
Claims
1. A crystalline form of a pharmaceutically acceptable salt of a compound of Formula I, the pharmaceutically acceptable salt of the compound of Formula I being a sodium salt; optionally, the crystalline form is Form 2, Form 3, Form 4, or Form 5; the compound of Formula I having the structural formula: ###00001### Formula I 2. The crystalline form of claim 1, wherein, The X-ray powder diffraction pattern of said crystalline Form 2 using Cu-Ka radiation has characteristic peaks at values of two theta at 5.42±0.2°, 10.57±0.2°, 19.41±0.2°; Optionally, the X-ray powder diffraction pattern of said crystalline Form 2 using Cu-Ka radiation further has characteristic peaks at values of two theta at one or more of the following: 10.8±0.2°, 11.87±0.2°, 14.11±0.2°, 15.21±0.2°, 16.22±0.2°, 17.11±0.2°, 21.15±0.2°, 21.57±0.2°, 22.35±0.2°, 23.55±0.2°, 24.16±0.2°.
3. The crystalline form of claim 2, wherein, Said crystalline Form 2 has an XRPD pattern as shown in Figure 7.
4. The crystalline form of any one of claims 1-3, wherein, The X-ray powder diffraction pattern of said crystalline Form 3 using Cu-Ka radiation has characteristic peaks at values of two theta at 4.60±0.2°, 5.72±0.2°, 5.98±0.2°, 7.23±0.2°, 14.50±0.2°, 15.40±0.2°, 18.39±0.2°; Optionally, the X-ray powder diffraction pattern of said crystalline Form 3 using Cu-Ka radiation further has characteristic peaks at values of two theta at one or more of the following: 8.35±0.2°, 8.74±0.2°, 11.97±0.2°, 14.95±0.2°, 15.94±0.2°, 17.18±0.2°, 20.62±0.2°, 22.58±0.2°, 26.99±0.2°.
5. The crystalline form of claim 4, wherein, Said crystalline Form 3 has an XRPD pattern as shown in Figure 10.
6. The crystalline form of any one of claims 1-5, wherein, The X-ray powder diffraction pattern of said crystalline Form 4 using Cu-Ka radiation has characteristic peaks at values of two theta at 5.08±0.2°, 6.88±0.2°; Optionally, the X-ray powder diffraction pattern of said crystalline Form 4 using Cu-Ka radiation further has characteristic peaks at values of two theta at one or more of the following: 4.75±0.2°, 5.85±0.2°, 9.91±0.2°, 14.17±0.2°, 18.84±0.2°, 20.58±0.2°.
7. The crystalline form of claim 6, wherein, Said crystalline Form 4 has an XRPD pattern as shown in Figure 13.
8. The crystalline form of any one of claims 1-7, wherein, The X-ray powder diffraction pattern of said crystalline Form 5 using Cu-Ka radiation has characteristic peaks at values of two theta at 5.26±0.2°, 8.09±0.2°, 15.31±0.2°, 20.18±0.2°; Optionally, the X-ray powder diffraction pattern of said crystallline Form 5 using Cu-Ka radiation further has characteristic peaks at values of two theta at one or more of: 9.29±0.2°, 10.49±0.2°, 12.99±0.2°, 15.72±0.2°, 23.17±0.2°, 23.61±0.2°, 24.30±0.2°.
9. The morphic form of claim 8, wherein, The Form 5 has an XRPD pattern as shown in FIG.
16.
10. A pharmaceutical composition comprising one or more of the crystalline forms of a pharmaceutically acceptable salt of a compound of Formula I of any one of claims 1 to 9 and optionally, a pharmaceutically acceptable excipient.
11. A crystalline form of a pharmaceutically acceptable salt of a compound of Formula I of any one of claims 1 to 9 or a pharmaceutical composition of claim 10 for use as: (i) an NLRP3 inflammasome inhibitor; and / or (ii) a modulator of one or more of IL-1 beta, IL-17, IL-18, IL-1 alpha, IL-37, IL-33, and Th17 cells.
12. A crystalline form of a pharmaceutically acceptable salt of a compound of Formula I of any one of claims 1 to 9 or a pharmaceutical composition of claim 10 for use in the treatment or prevention of a disease, disorder, or condition, wherein the disease, disorder, or condition is selected from the group consisting of: (i) an immune system disease, disorder, or condition; (ii) an inflammatory disease, disorder, or condition or an autoimmune disease, disorder, or condition; (iii) a skin disease, disorder, or condition; (iv) a cardiovascular system disease, disorder, or condition; (v) a tumor; (vi) a renal system disease, disorder, or condition; (vii) a gastrointestinal tract disease, disorder, or condition; (viii) a respiratory system disease, disorder, or condition; (ix) an endocrine system disease, disorder, or condition; (x) a central nervous system (CNS) disease, disorder, or condition; and / or (xi) a local or systemic infection.
13. Use of a crystalline form of a pharmaceutically acceptable salt of a compound of Formula I of any one of claims 1 to 9 or a pharmaceutical composition of claim 10 in the manufacture of a medicament for the treatment or prevention of a disease, disorder, or condition, wherein the disease, disorder, or condition is selected from the group consisting of: (i) an immune system disease, disorder, or condition; (ii) an inflammatory disease, disorder, or condition or an autoimmune disease, disorder, or condition; (iii) a skin disease, disorder, or condition; (iv) a cardiovascular system disease, disorder, or condition; (v) a tumor; (vi) a renal system disease, disorder, or condition; (ix) an endocrine system disease, disorder, or (x) a central nervous system (CNS) disease, disorder, or condition; and / or (xi) a local or systemic infection.
14. A method of treating or preventing a disease, disorder, or condition, comprising administering to a subject in need thereof a crystalline form of a pharmaceutically acceptable salt of a compound of Formula I according to any one of claims 1 to 9 or a pharmaceutical composition according to claim 10, wherein the disease, disorder, or condition is selected from the group consisting of: (i) immune system disease, disorder, or condition; (ii) an inflammatory disease, disorder, or condition, or an autoimmune disease, disorder, or condition; (iii) a skin disease, disorder,or condition; (iv) a cardiovascular system disease, disorder, or condition; (v) a tumor; (ix) an endocrine system disease, disorder, or (vi) a renal system disease, disorder or condition; (vii) a gastrointestinal tract disease, disorder or condition; (viii) a respiratory system disease, disorder or condition; (ix) an endocrine system disease, disorder or condition; (x) a central nervous system (CNS) disease, disorder or condition; and / or (xi) a local or systemic infection.
15. The crystalline form of a pharmaceutically acceptable salt of a compound of Formula I or the pharmaceutical composition for use according to claim 12, the use according to claim 13, or the method according to claim 14, wherein, The disease, disorder or condition is selected from the group consisting of: constitutive inflammation, including cryopyrin-associated periodic syndromes (CAPS), Muckle-Wells syndrome (MWS), familial cold autoinflammatory syndrome (FCAS) and neonatal-onset multisystem inflammatory disease (NOMID), familial Mediterranean fever (FMF), TNF receptor associated periodic syndrome (TRAPS), mevalonate kinase deficiency (MKD), hyperimmunoglobulinemia D and periodic fever syndrome (HIDS), interleukin 1 receptor antagonist deficiency (DIRA), Majeed syndrome, pyogenic arthritis, pyoderma gangrenosum, and acne syndrome (PAPA), A20 haploinsufficiency (HA20), pediatric granulomatous arthritis (PGA), PLCG2-associated antibody deficiency and immune dysregulation (PLAID), PLCG2-associated autoinflammation, antibody deficiency, and immune dysregulation (APLAID), sideroblastic anemia with B-cell immunodeficiency, periodic fevers, and developmental delay (SIFD); autoimmune diseases, including multiple sclerosis (MS), type 1 diabetes, psoriasis, rheumatoid arthritis, Behcet’s disease, Sjogren’s syndrome, and Schnitzler’s syndrome; macrophage activation syndrome; Blau syndrome; respiratory diseases, including chronic obstructive pulmonary disorder (COPD), asthma such as allergic asthma and steroid-resistant asthma, asbestosis, silicosis, and cystic fibrosis; dermatitis, including contact dermatitis; central nervous system diseases, including Parkinson’s disease, Alzheimer’s disease, motor neuron disease, Huntington’s disease, brain damage caused by cerebral malaria, and pneumococcal meningitis; metabolic diseases, including type 2 diabetes, atherosclerosis, obesity, gout, pseudogout; ocular diseases, including those of the ocular epithelium, age-related macular degeneration (AMD), uveitis, corneal infections, and dry eye; renal diseases, including chronic kidney disease, oxalate nephropathy, nephrocalcinosis, and diabetic nephropathy; liver diseases, including nonalcoholic steatohepatitis (NASH) and alcoholic liver disease; cutaneous inflammatory reactions, including contact hypersensitivity and sunburn; arthritic reactions, including osteoarthritis, systemic juvenile idiopathic arthritis, adult-onset Still’s disease, relapsing polychondritis; viral infections, including alphaviruses (Chikungunya virus, Ross River virus) and flaviviruses (dengue virus, Zika virus), influenza virus, HIV; Hidradenitis Suppurativa (HS) and other cyst-causing skin diseases; cancers, including lung cancer metastasis, pancreatic cancer, gastric cancer, myelodysplastic syndrome, leukemia; polymyositis; stroke, including ischemic stroke; myocardial infarction, including recurrent myocardial infarction; congestive heart failure; embolism; cardiovascular disease; graft versus host disease; hypertension; colitis; helminth infection; bacterial infection; sepsis; septic shock; abdominal aortic aneurysm; wound healing; depression, psychological stress; ischemia-reperfusion injury and any disease in which an individual has been determined to carry a germline or somatic non-silent mutation in NLRP3.
16. The crystalline form of the pharmaceutically acceptable sodium salt of the compound of Formula I or the pharmaceutical composition for use according to claim 12, the use according to claim 13, or the method according to claim 14, wherein, The disease, disorder or condition is selected from the group consisting of: (i) an autoinflammatory disease such as cryopyrin-associated periodic syndromes (CAPS), Muckle-Wells syndrome (MWS), familial cold autoinflammatory syndrome (FCAS), familial Mediterranean fever (FMF), neonatal-onset multisystem inflammatory disease (NOMID), tumor necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS), hyperimmunoglobulinemia D and periodic fever syndrome (HIDS), interleukin 1 receptor antagonist deficiency (DIRA), Majeed syndrome, or pyogenic arthritis, pyoderma gangrenosum, and acne syndrome (PAPA); (ii) Parkinson’s disease or Huntington’s disease; (iii) gout or juvenile idiopathic arthritis; (iv) nonalcoholic steatohepatitis (NASH); (v) oxalate nephropathy or nephrocalcinosis; (vi) uveitis; (vii) hidradenitis suppurativa (HS); (viii) myelodysplastic syndrome, macrophage activation syndrome, Schnitzler syndrome, adult-onset Still’s disease, or Behcet’s disease; or (ix) sepsis, septic shock.
